Report Overview
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size was estimated at USD 5387 million in 2023 and is projected to reach USD 7868.75 million by 2032, exhibiting a CAGR of 4.30% during the forecast period.
North America Glucagon-like peptide 1 (GLP-1)-based Therapies market size was estimated at USD 1509.08 million in 2023, at a CAGR of 3.69% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Glucagon-like peptide 1 (GLP-1)-based Therapies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Glucagon-like peptide 1 (GLP-1)-based Therapies market in any manner.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Market Segmentation (by Type)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segmentation (by Application)
Hospital
Pharmacy
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market
Overview of the regional outlook of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Glucagon-like peptide 1 (GLP-1)-based Therapies, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Key Market Segments
1.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview
2.1 Global Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Landscape
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2019-2025)
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2019-2025)
3.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites, Area Served, Product Type
3.6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
3.6.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
3.6.2 Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Glucagon-like peptide 1 (GLP-1)-based Therapies Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2025)
6.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Market Share by Type (2019-2025)
6.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2019-2025)
7 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales by Application (2019-2025)
7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Application (2019-2025)
7.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2025)
8 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Consumption by Region
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region
8.2 North America
8.2.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Production by Region
9.1 Global Production of Glucagon-like peptide 1 (GLP-1)-based Therapies by Region (2019-2025)
9.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2019-2025)
9.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production
9.4.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2019-2025)
9.4.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production
9.5.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2019-2025)
9.5.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2025)
9.6.1 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2019-2025)
9.6.2 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2025)
9.7.1 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2019-2025)
9.7.2 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Novo Nordisk
10.1.1 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.1.4 Novo Nordisk Business Overview
10.1.5 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
10.1.6 Novo Nordisk Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 Eli Lily
10.3.1 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
10.3.5 Eli Lily Business Overview
10.3.6 Eli Lily Recent Developments
10.4 GSK
10.4.1 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.4.4 GSK Business Overview
10.4.5 GSK Recent Developments
10.5 Sanofi
10.5.1 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.5.4 Sanofi Business Overview
10.5.5 Sanofi Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.6.4 Bristol-Myers Squibb Business Overview
10.6.5 Bristol-Myers Squibb Recent Developments
10.7 Abbott Laboratories
10.7.1 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
10.7.2 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.7.4 Abbott Laboratories Business Overview
10.7.5 Abbott Laboratories Recent Developments
11 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
11.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast
11.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
11.2.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
11.2.4 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2032)
12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2032)
12.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Application (2025-2032)
12.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) Forecast by Application
12.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Comparison by Region (M USD)
Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2022)
Table 10. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites and Area Served
Table 12. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Type
Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (K MT)
Table 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Type (2019-2025)
Table 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2025)
Table 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Type (2019-2025)
Table 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Share by Type (2019-2025)
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (USD/MT) by Type (2019-2025)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Application
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2025) & (K MT)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2025)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2025) & (M USD)
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2019-2025)
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2025)
Table 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2025) & (K MT)
Table 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2025)
Table 38. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2025) & (K MT)
Table 39. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2025) & (K MT)
Table 41. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2025) & (K MT)
Table 43. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) by Region (2019-2025)
Table 44. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2019-2025)
Table 46. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 52. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 53. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Novo Nordisk Business Overview
Table 55. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 56. Novo Nordisk Recent Developments
Table 57. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 58. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 59. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 62. AstraZeneca Recent Developments
Table 63. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 64. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 65. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 67. Eli Lily Business Overview
Table 68. Eli Lily Recent Developments
Table 69. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 70. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 71. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. GSK Business Overview
Table 73. GSK Recent Developments
Table 74. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 75. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 76. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Sanofi Business Overview
Table 78. Sanofi Recent Developments
Table 79. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 80. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 81. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Recent Developments
Table 84. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 85. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 86. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Abbott Laboratories Business Overview
Table 88. Abbott Laboratories Recent Developments
Table 89. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2025-2032) & (K MT)
Table 90. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2025-2032) & (M USD)
Table 91. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2032) & (K MT)
Table 92. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2032) & (M USD)
Table 93. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2032) & (K MT)
Table 94. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2032) & (M USD)
Table 95. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2025-2032) & (K MT)
Table 96. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2025-2032) & (M USD)
Table 97. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2032) & (K MT)
Table 98. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2032) & (M USD)
Table 99. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Forecast by Country (2025-2032) & (Units)
Table 100. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2032) & (M USD)
Table 101. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2025-2032) & (K MT)
Table 102. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2032) & (M USD)
Table 103. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2025-2032) & (USD/MT)
Table 104. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) Forecast by Application (2025-2032)
Table 105. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD), 2019-2032
Figure 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) (2019-2032)
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (M USD)
Figure 11. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2023
Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2023
Figure 13. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type
Figure 18. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2025)
Figure 19. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2023
Figure 20. Market Size Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2025)
Figure 21. Market Size Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application
Figure 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2025)
Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application in 2023
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2019-2025)
Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2023
Figure 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2025)
Figure 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2025)
Figure 30. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 32. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 37. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2023
Figure 44. China Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 50. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 51. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Region (2019-2025)
Figure 62. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2019-2025)
Figure 65. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Type (2025-2032)
Figure 70. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2025-2032)
Figure 71. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Application (2025-2032)
